Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Oxaliplatin formulation MBP-426 well tolerated in phase I study

Nov. 6, 2007

Nereus Pharmaceuticals' NPI-0052, NPI-2358 assessed in phase I cancer studies

Nov. 6, 2007

New data on oblimersen pharmacokinetics, in vivo activity reported

Nov. 6, 2007

Enzon initiates phase I study of EZN-2968 to evaluate additional dosing schedule

Nov. 5, 2007

MGCD-0103 and gemcitabine given in combination to patients with solid tumors

Nov. 5, 2007

Antitumor effects seen with JX-594 in patients with liver tumors

Nov. 5, 2007

Preclinical and clinical profile of BIIB-021, an Hsp90 inhibitor with antitumor activity

Nov. 5, 2007

Novel compounds overcome drug resistance in tumors expressing BCRP

Nov. 5, 2007

DTS-201 safe in first-in-man study

Nov. 5, 2007

Results from phase III registration trial of satraplatin fail to achieve statistical significance

Nov. 2, 2007

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...